Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 7/20 | 0.81 |
| ▸ | THRB | P10828 | 2/20 | 0.67 |
| ▸ | POLB | P06746 | 1/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.66 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 10/20 | 0.64 |
| ▸ | MEN1 | O00255 | 5/20 | 0.64 |
| ▸ | MITF | O75030 | 2/20 | 0.62 |
| ▸ | LMNA | P02545 | 2/20 | 0.62 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.61 |
| ▸ | CRHBP | P24387 | 1/20 | 0.58 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.58 |
| ▸ | USP2 | O75604 | 2/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21651804 | 0.91 | MAPT (0.98) | MAPTTHRBPOLBALDH1A1SMN1; SMN2 | |
| SCHEMBL8288656 | 0.88 | MAPT (0.84) | MAPTALDH1A1SMN1; SMN2KMT2AMEN1 | |
| SCHEMBL8290348 | 0.84 | MAPT (0.75) | MAPTALDH1A1SMN1; SMN2KMT2AMEN1 | |
| SCHEMBL8288765 | 0.80 | MAPT (0.98) | MAPTALDH1A1SMN1; SMN2KMT2AMEN1 | |
| SCHEMBL23711006 | 0.80 | KDM4E (0.62) | MAPTALDH1A1SMN1; SMN2KMT2AMEN1 | |
| SCHEMBL23711000 | 0.80 | MAPT (0.59) | MAPTALDH1A1SMN1; SMN2KMT2AMEN1 | |
| SCHEMBL21651864 | 0.74 | MAPT (0.70) | MAPTTHRBPOLBALDH1A1SMN1; SMN2 | |
| SCHEMBL14666761 | 0.73 | MAPT (0.63) | MAPTALDH1A1SMN1; SMN2KMT2ALMNA | |
| SCHEMBL14670380 | 0.72 | TP53 (0.71) | MAPTALDH1A1SMN1; SMN2KMT2AMEN1 | |
| SCHEMBL24337259 | 0.72 | MAPT (0.70) | MAPTTHRBPOLBALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230132397-A9 | USE OF TOLL-LIKE RECEPTOR 2 (TLR-2) AGONIST FOR MODULATING HUMAN IMMUNE RESPONSE | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2023-04-27 | — | — | US | disclosed |
| US-20220118085-A9 | USE OF TOLL-LIKE RECEPTOR 2 (TLR-2) AGONIST FOR MODULATING HUMAN IMMUNE RESPONSE | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2022-04-21 | — | — | US | disclosed |
| US-20210236632-A1 | USE OF TOLL-LIKE RECEPTOR 2 (TLR-2) AGONIST FOR MODULATING HUMAN IMMUNE RESPONSE | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2021-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220118085-A9 | USE OF TOLL-LIKE RECEPTOR 2 (TLR-2) AGONIST FOR MODULATING HUMAN IMMUNE RESPONSE | TLR2, TLR1, TLR3 | MAPT 206/4885THRB 112/4885POLB 1547/4885 |
| US-20230132397-A9 | USE OF TOLL-LIKE RECEPTOR 2 (TLR-2) AGONIST FOR MODULATING HUMAN IMMUNE RESPONSE | TLR2, TLR1, TLR3 | MAPT 206/4885THRB 112/4885POLB 1547/4885 |
| US-20210236632-A1 | USE OF TOLL-LIKE RECEPTOR 2 (TLR-2) AGONIST FOR MODULATING HUMAN IMMUNE RESPONSE | TLR2, TLR1, TLR3 | MAPT 206/4885THRB 112/4885POLB 1547/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.